Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass in adult patients undergoing cardiac surgery

• Published in: European journal of clinical pharmacology 2021-05, Vol.77 (5), p.735-745
• Main Authors: Asada, Mizuho, Nagata, Masashi, Mizuno, Tomohiro, Uchida, Tokujiro, Takahashi, Hiromitsu, Makita, Koshi, Arai, Hirokuni, Kijima, Shinichi, Echizen, Hirotoshi, Yasuhara, Masato
• Format: Article
• Language: English
• Subjects: Antibiotics; Biomedical and Life Sciences; Biomedicine; Cefazolin; Dosage; Drug dosages; Heart; Heart surgery; Minimum inhibitory concentration; Pathogens; Pharmacokinetics; Pharmacokinetics and Disposition; Pharmacology/Toxicology; Prophylaxis; Surgical site infections
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/s00228-020-03045-1

Purpose The aims of the present study were to establish a population pharmacokinetic (PPK) model of cefazolin for adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) and to assess the probability of target attainment (PTA) for the prophylaxis of surgical site infection (SSI) using cefazolin. Methods Adult patients who underwent cardiac surgery with CPB were enrolled in the prospective study. Blood samples for plasma cefazolin assay were collected, and total and unbound drug concentrations were measured and analysed using the nonlinear mixed-effects modelling (NONMEM) software considering saturable plasma protein binding. Using the PPK model, plasma unbound cefazolin concentration-time courses with current prophylaxis protocols were simulated, and the PTA for common SSI pathogens was estimated. Results A total of 199 blood samples were obtained from 27 patients. A one-compartment model with first-order elimination plus an on/off CPB compartment best described the data. The population mean for systemic drug clearance (CL) was reduced and that for the volume of distribution ( V ) was increased during CPB compared with the pre-CPB values. CPB-induced hypoalbuminemia was associated with reduced maximum protein binding ( B max ). The simulation studies suggested that the current dosing protocols are insufficient for attaining PTA > 0.9 throughout surgery against pathogens with minimum inhibitory concentrations (MICs) > 8 mg/L. A new dosing protocol that achieves a PTA > 0.9 for pathogens with a MIC of 16 mg/L was proposed. Conclusion PPK modelling with simulation may be valuable for devising a cefazolin prophylaxis protocol for patients undergoing cardiac surgery with CPB.